JP2006522775A - 置換された4−フェニル−4−’1h−イミダゾール−2−イル!−ピペリジン誘導体および抗抑鬱および不安緩解活性を有する選択性非ペプチドデルタオピオイドアゴニストとしてのそれらの使用 - Google Patents

置換された4−フェニル−4−’1h−イミダゾール−2−イル!−ピペリジン誘導体および抗抑鬱および不安緩解活性を有する選択性非ペプチドデルタオピオイドアゴニストとしてのそれらの使用 Download PDF

Info

Publication number
JP2006522775A
JP2006522775A JP2006505540A JP2006505540A JP2006522775A JP 2006522775 A JP2006522775 A JP 2006522775A JP 2006505540 A JP2006505540 A JP 2006505540A JP 2006505540 A JP2006505540 A JP 2006505540A JP 2006522775 A JP2006522775 A JP 2006522775A
Authority
JP
Japan
Prior art keywords
het
alkyl
group
phenyl
imidazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006505540A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006522775A5 (cg-RX-API-DMAC7.html
Inventor
シユテクラー,トマス・ホルスト・ボルフガング
ジヤンセン,フラン・エドウアール
レーネルツ,ジヨセフ・エリザベト
フエルナンデス−ガデア,フランシスコ・ザビエル
ゴメス−サンチエス,アントニオ
メールト,テオ・フラン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of JP2006522775A publication Critical patent/JP2006522775A/ja
Publication of JP2006522775A5 publication Critical patent/JP2006522775A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2006505540A 2003-04-11 2004-04-08 置換された4−フェニル−4−’1h−イミダゾール−2−イル!−ピペリジン誘導体および抗抑鬱および不安緩解活性を有する選択性非ペプチドデルタオピオイドアゴニストとしてのそれらの使用 Withdrawn JP2006522775A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP0303879 2003-04-11
PCT/EP2004/050492 WO2004089372A1 (en) 2003-04-11 2004-04-08 Substituted 4-phenyl-4-`1h-imidazol-2-yl !-piperidine derivatives and their use as selective non-peptide delta opioid agonists with antidepressant and anxiolytic activity

Publications (2)

Publication Number Publication Date
JP2006522775A true JP2006522775A (ja) 2006-10-05
JP2006522775A5 JP2006522775A5 (cg-RX-API-DMAC7.html) 2007-06-07

Family

ID=33154992

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006505540A Withdrawn JP2006522775A (ja) 2003-04-11 2004-04-08 置換された4−フェニル−4−’1h−イミダゾール−2−イル!−ピペリジン誘導体および抗抑鬱および不安緩解活性を有する選択性非ペプチドデルタオピオイドアゴニストとしてのそれらの使用

Country Status (12)

Country Link
US (1) US20060287345A1 (cg-RX-API-DMAC7.html)
EP (1) EP1615644B1 (cg-RX-API-DMAC7.html)
JP (1) JP2006522775A (cg-RX-API-DMAC7.html)
AR (1) AR044010A1 (cg-RX-API-DMAC7.html)
AT (1) ATE353649T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004228960A1 (cg-RX-API-DMAC7.html)
CA (1) CA2521186A1 (cg-RX-API-DMAC7.html)
CL (1) CL2004000754A1 (cg-RX-API-DMAC7.html)
DE (1) DE602004004771T2 (cg-RX-API-DMAC7.html)
ES (1) ES2282858T3 (cg-RX-API-DMAC7.html)
TW (1) TW200509913A (cg-RX-API-DMAC7.html)
WO (1) WO2004089372A1 (cg-RX-API-DMAC7.html)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011030565A (ja) * 2009-07-06 2011-02-17 Yokohama City Univ 社会的隔離モデル動物
JP2016519161A (ja) * 2013-05-24 2016-06-30 アルカームス ファーマ アイルランド リミテッド モルファン及びモルフィナン類似物及び使用の方法
KR20180002616A (ko) 2015-03-17 2018-01-08 고쿠리쯔 다이가쿠 호징 츠쿠바 다이가쿠 모르피난 유도체
WO2018030382A1 (ja) 2016-08-09 2018-02-15 国立大学法人 筑波大学 モルヒナン誘導体
WO2018052114A1 (ja) 2016-09-16 2018-03-22 国立大学法人 筑波大学 モルヒナン誘導体のオピオイドδ受容体アゴニスト関連疾患の治療のための使用
WO2021100878A1 (ja) 2019-11-22 2021-05-27 学校法人北里研究所 ピラゾロモルヒナン誘導体
JP2021523102A (ja) * 2018-05-01 2021-09-02 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. スピロピペリジン系ニコチン性アセチルコリン受容体アロステリック調節剤
KR20230152039A (ko) 2021-02-26 2023-11-02 갓코호우징 도쿄리카다이가쿠 스트레스 관련 장애의 치료 또는 예방용 의약 조성물
JP2024511169A (ja) * 2021-03-26 2024-03-12 ピーエックス・アイエヌジー,エルエルシー 運動誘発性精神疲労を低減するためのパラキサンチンの使用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1390848B1 (it) 2008-07-31 2011-10-19 Neuroscienze Pharmaness S C A R L Composti farmaceutici
EP2149370A1 (en) 2008-07-31 2010-02-03 Neuroscienze Pharmaness S.C. A R.L. Diazabicyclic compounds and microemulsions thereof
IT1396951B1 (it) 2009-12-18 2012-12-20 Neuroscienze Pharmaness S C A R L Composti farmaceutici

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354863A (en) * 1992-01-21 1994-10-11 G. D. Searle & Co. Opioid agonist compounds
DE19805370A1 (de) * 1997-03-14 1998-09-17 Gruenenthal Gmbh Substituierte Aminoverbindungen und ihre Verwendung als analgetisch wirksame Substanzen
HN1999000149A (es) * 1998-09-09 2000-01-12 Pfizer Prod Inc Derivados de 4,4-biarilpiperidina
EP1038872A1 (en) * 1999-02-22 2000-09-27 Pfizer Products Inc. 4-Phenyl-4-heteroarylpiperdine derivatives as opioid receptor ligands
DE19939044A1 (de) * 1999-08-18 2001-03-15 Gruenenthal Gmbh Verwendung von Morphinanderivaten als Arzneimittel
SE0101767D0 (sv) * 2001-05-18 2001-05-18 Astrazeneca Ab Novel compounds
CA2462374C (en) * 2001-10-15 2011-01-18 Janssen Pharmaceutica N.V. Substituted 4-phenyl-4-(1h-imidazol-2-yl)-piperidine derivatives for reducing ischaemic damage
JP4417108B2 (ja) * 2001-10-15 2010-02-17 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 新規な置換された4−フェニル−4−[1h−イミダゾール−2−イル]−ピペリジン誘導体および選択的非ペプチドデルタオピオイドアゴニストとしてのそれらの使用

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011030565A (ja) * 2009-07-06 2011-02-17 Yokohama City Univ 社会的隔離モデル動物
JP2016519161A (ja) * 2013-05-24 2016-06-30 アルカームス ファーマ アイルランド リミテッド モルファン及びモルフィナン類似物及び使用の方法
EP3974430A1 (en) 2015-03-17 2022-03-30 Nippon Chemiphar Co., Ltd. Morphinan derivative
US11643411B2 (en) 2015-03-17 2023-05-09 Nippon Chemiphar Co., Ltd. Morphinan derivative
KR20230104767A (ko) 2015-03-17 2023-07-10 닛뽕 케미파 가부시키가이샤 모르피난 유도체
US10442802B2 (en) 2015-03-17 2019-10-15 Nippon Chemiphar Co., Ltd. Morphinan derivative
KR20180002616A (ko) 2015-03-17 2018-01-08 고쿠리쯔 다이가쿠 호징 츠쿠바 다이가쿠 모르피난 유도체
US10995092B2 (en) 2015-03-17 2021-05-04 Nippon Chemiphar Co., Ltd. Morphinan derivative
WO2018030382A1 (ja) 2016-08-09 2018-02-15 国立大学法人 筑波大学 モルヒナン誘導体
US11633392B2 (en) 2016-09-16 2023-04-25 Nippon Chemiphar Co., Ltd. Use of morphinan derivative for therapeutic treatment of opioid delta receptor agonist-related disease
US12109209B2 (en) 2016-09-16 2024-10-08 Nippon Chemiphar Co., Ltd. Use of morphinan derivatives for treatment of opioid delta receptor agonist-related disease
KR20200024120A (ko) 2016-09-16 2020-03-06 닛뽕 케미파 가부시키가이샤 모르피난 유도체의 오피오이드 δ 수용체 아고니스트 관련 질환의 치료를 위한 사용
EP4414037A2 (en) 2016-09-16 2024-08-14 Nippon Chemiphar Co., Ltd. Morphinan derivatives for the treatment of opioid delta receptor agonist-related diseases
WO2018052114A1 (ja) 2016-09-16 2018-03-22 国立大学法人 筑波大学 モルヒナン誘導体のオピオイドδ受容体アゴニスト関連疾患の治療のための使用
US11332463B2 (en) 2018-05-01 2022-05-17 Merck Sharp & Dohme Corp. Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors
JP7073533B2 (ja) 2018-05-01 2022-05-23 メルク・シャープ・アンド・ドーム・コーポレーション スピロピペリジン系ニコチン性アセチルコリン受容体アロステリック調節剤
JP2021523102A (ja) * 2018-05-01 2021-09-02 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. スピロピペリジン系ニコチン性アセチルコリン受容体アロステリック調節剤
EP4062972A1 (en) 2019-11-22 2022-09-28 The Kitasato Institute Pyrazolomorphinan derivative
WO2021100878A1 (ja) 2019-11-22 2021-05-27 学校法人北里研究所 ピラゾロモルヒナン誘導体
KR20230152039A (ko) 2021-02-26 2023-11-02 갓코호우징 도쿄리카다이가쿠 스트레스 관련 장애의 치료 또는 예방용 의약 조성물
JP2024511169A (ja) * 2021-03-26 2024-03-12 ピーエックス・アイエヌジー,エルエルシー 運動誘発性精神疲労を低減するためのパラキサンチンの使用

Also Published As

Publication number Publication date
DE602004004771D1 (de) 2007-03-29
EP1615644B1 (en) 2007-02-14
ATE353649T1 (de) 2007-03-15
CL2004000754A1 (es) 2005-02-25
AR044010A1 (es) 2005-08-24
WO2004089372A1 (en) 2004-10-21
US20060287345A1 (en) 2006-12-21
EP1615644A1 (en) 2006-01-18
ES2282858T3 (es) 2007-10-16
CA2521186A1 (en) 2004-10-21
DE602004004771T2 (de) 2007-12-06
TW200509913A (en) 2005-03-16
AU2004228960A1 (en) 2004-10-21

Similar Documents

Publication Publication Date Title
US6395742B1 (en) 2,4-diaminopyrimidine derivatives
US20080096925A1 (en) Novel Substituted 4-Phenyl-4[H-Imidazol-2-YL]-Piperidine Derivatived And Their Use As Selective Non-Peptide Delta Opioid Agonists
US20100168167A1 (en) Piperidinones Useful in the Treatment of Inflammation
TW200808744A (en) Novel diazepan derivatives
US20030236267A1 (en) Benzimidazole derivatives
EA009217B1 (ru) Замещенные производные 1,4-дипиперидин-4-илпиперазина и их применение в качестве нейрокининовых антагонистов
EA015681B1 (ru) Производные пипередин-4-ил-пиридазин-3-иламина как быстро диссоциирующие антагонисты рецептора дофамина 2
EP1615644B1 (en) Substituted 4-phenyl-4-[1h-imidazol-2-yl]-piperidine derivatives and their use as selective non-peptide delta opioid agonists with antidepressant and anxiolytic activity
AU2002346994A1 (en) Novel substituted 4-phenyl-4-[1H-imidazol-2-yl]-piperidine derivatives and their use as selective non-peptide delta opioid agonists
JP2023522078A (ja) 1,5-ジヒドロ-2,4-ベンゾジアゼピン-3-オン誘導体及びその使用
JP2001515899A (ja) テトラヒドロガンマ−カルボリン類
JP2006527236A (ja) オピオイド鎮痛薬と組合せた置換1,4−ジ−ピペリジン−4−イル−ピペラジン誘導体ならびに疼痛およびオピオイドに基づく処置に伴う副作用の処置のためのそれらの使用
EP1438049A2 (en) Substituted 4-phenyl-4-(1h-imidazol-2-yl)-piperidine derivatives for reducing ischaemic damage
JP2002532480A (ja) モルホリノン及びモルホリン誘導体、ならびにその使用
US7635696B2 (en) Isoxazoline-indole derivatives with an improved antipsychotic and anxiolytic activity
MXPA06004626A (es) Indoles sustituidos con piperidina o sus heteroderivados y su uso como moduladores del receptor de quemocina (ccr3).
JP3091844B2 (ja) 複素環式化合物
KR20260061051A (ko) 헤테로사이클 화합물 및 이의 용도
WO2006083711A1 (en) Tachykinin receptor antagonists
TW201242947A (en) New azaspirodecanone compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070404

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070404

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20070730